376 related articles for article (PubMed ID: 32157732)
1. Harnessing the immune system via FcγR function in immune therapy: a pathway to next-gen mAbs.
Chenoweth AM; Wines BD; Anania JC; Mark Hogarth P
Immunol Cell Biol; 2020 Apr; 98(4):287-304. PubMed ID: 32157732
[TBL] [Abstract][Full Text] [Related]
2. Expression of a Recombinant High Affinity IgG Fc Receptor by Engineered NK Cells as a Docking Platform for Therapeutic mAbs to Target Cancer Cells.
Snyder KM; Hullsiek R; Mishra HK; Mendez DC; Li Y; Rogich A; Kaufman DS; Wu J; Walcheck B
Front Immunol; 2018; 9():2873. PubMed ID: 30574146
[TBL] [Abstract][Full Text] [Related]
3. The role of IgG Fc receptors in antibody-dependent enhancement.
Bournazos S; Gupta A; Ravetch JV
Nat Rev Immunol; 2020 Oct; 20(10):633-643. PubMed ID: 32782358
[TBL] [Abstract][Full Text] [Related]
4. Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs.
Mimoto F; Kadono S; Katada H; Igawa T; Kamikawa T; Hattori K
Mol Immunol; 2014 Mar; 58(1):132-8. PubMed ID: 24334029
[TBL] [Abstract][Full Text] [Related]
5. The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies.
Gogesch P; Dudek S; van Zandbergen G; Waibler Z; Anzaghe M
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445651
[TBL] [Abstract][Full Text] [Related]
6. Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.
Stavenhagen JB; Gorlatov S; Tuaillon N; Rankin CT; Li H; Burke S; Huang L; Vijh S; Johnson S; Bonvini E; Koenig S
Cancer Res; 2007 Sep; 67(18):8882-90. PubMed ID: 17875730
[TBL] [Abstract][Full Text] [Related]
7. Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens.
Waight JD; Chand D; Dietrich S; Gombos R; Horn T; Gonzalez AM; Manrique M; Swiech L; Morin B; Brittsan C; Tanne A; Akpeng B; Croker BA; Buell JS; Stein R; Savitsky DA; Wilson NS
Cancer Cell; 2018 Jun; 33(6):1033-1047.e5. PubMed ID: 29894690
[TBL] [Abstract][Full Text] [Related]
8. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody.
Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D
Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous exposure to FcγR and FcαR on monocytes and macrophages enhances antitumor activity in vivo.
Li B; Xu L; Tao F; Xie K; Wu Z; Li Y; Li J; Chen K; Pi C; Mendelsohn A; Larrick JW; Gu H; Fang J
Oncotarget; 2017 Jun; 8(24):39356-39366. PubMed ID: 28454118
[TBL] [Abstract][Full Text] [Related]
10. Characterization of anti-SARS-CoV-2 monoclonal antibodies focusing on antigen binding, neutralization, and FcγR activation via formation of immune complex.
Tada M; Aoyama M; Ishii-Watabe A
MAbs; 2023; 15(1):2222874. PubMed ID: 37309192
[TBL] [Abstract][Full Text] [Related]
11. FcγRΙΙB controls the potency of agonistic anti-TNFR mAbs.
White AL; Chan HT; French RR; Beers SA; Cragg MS; Johnson PW; Glennie MJ
Cancer Immunol Immunother; 2013 May; 62(5):941-8. PubMed ID: 23543215
[TBL] [Abstract][Full Text] [Related]
12. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19).
Shanmugaraj B; Siriwattananon K; Wangkanont K; Phoolcharoen W
Asian Pac J Allergy Immunol; 2020 Mar; 38(1):10-18. PubMed ID: 32134278
[TBL] [Abstract][Full Text] [Related]
13. [Characterization of Therapeutic Monoclonal Antibodies by Using FcγR-expressing Reporter Cell Lines].
Tada M; Ishii-Watabe A
Yakugaku Zasshi; 2017; 137(7):837-843. PubMed ID: 28674297
[TBL] [Abstract][Full Text] [Related]
14. Fc glycoengineering of a PD-L1 antibody harnesses Fcγ receptors for increased antitumor efficacy.
Cohen Saban N; Yalin A; Landsberger T; Salomon R; Alva A; Feferman T; Amit I; Dahan R
Sci Immunol; 2023 Mar; 8(81):eadd8005. PubMed ID: 36867679
[TBL] [Abstract][Full Text] [Related]
15. Mutation of the TGN1412 anti-CD28 monoclonal antibody lower hinge confers specific FcγRIIb binding and retention of super-agonist activity.
Chenoweth AM; Esparon S; Wines BD; Schuurman J; Labrijn AF; Hogarth PM
Immunol Cell Biol; 2023 Aug; 101(7):657-662. PubMed ID: 36997299
[TBL] [Abstract][Full Text] [Related]
16. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2.
Chi X; Yan R; Zhang J; Zhang G; Zhang Y; Hao M; Zhang Z; Fan P; Dong Y; Yang Y; Chen Z; Guo Y; Zhang J; Li Y; Song X; Chen Y; Xia L; Fu L; Hou L; Xu J; Yu C; Li J; Zhou Q; Chen W
Science; 2020 Aug; 369(6504):650-655. PubMed ID: 32571838
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody as a potential anti-COVID-19.
Jahanshahlu L; Rezaei N
Biomed Pharmacother; 2020 Sep; 129():110337. PubMed ID: 32534226
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies for the S2 subunit of spike of SARS-CoV-1 cross-react with the newly-emerged SARS-CoV-2.
Zheng Z; Monteil VM; Maurer-Stroh S; Yew CW; Leong C; Mohd-Ismail NK; Cheyyatraivendran Arularasu S; Chow VTK; Lin RTP; Mirazimi A; Hong W; Tan YJ
Euro Surveill; 2020 Jul; 25(28):. PubMed ID: 32700671
[TBL] [Abstract][Full Text] [Related]
19. Fc γ receptor compositional heterogeneity: Considerations for immunotherapy development.
Barb AW
J Biol Chem; 2021; 296():100057. PubMed ID: 33172893
[TBL] [Abstract][Full Text] [Related]
20. Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo.
Schäfer A; Muecksch F; Lorenzi JCC; Leist SR; Cipolla M; Bournazos S; Schmidt F; Maison RM; Gazumyan A; Martinez DR; Baric RS; Robbiani DF; Hatziioannou T; Ravetch JV; Bieniasz PD; Bowen RA; Nussenzweig MC; Sheahan TP
J Exp Med; 2021 Mar; 218(3):. PubMed ID: 33211088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
